Owlstone Medical, Actelion team up for pulmonary hypertension detection - PharmaTimes

Owlstone Medical, Actelion team up for pulmonary hypertension detection - PharmaTimes

Owlstone Medical, Actelion team up for pulmonary hypertension detection - PharmaTimes

Posted: 20 May 2019 05:14 AM PDT

Owlstone Medical has announced a strategic partnership with Actelion Pharmaceuticals.

The global leader in Breath Biopsy for applications in early disease detection announced the collaboration to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes. This development program will be solely funded by Actelion.

Currently, early diagnosis of PH is very difficult, and even at an advanced stage presents similar to other heart and lung conditions, so a delay of years between the onset of symptoms and diagnosis and treatment is unfortunately common.

The collaboration will initially involve collecting breath exhaled Volatile Organic Compounds (VOCs) from over 1,000 patients using Owlstone Medical's proprietary sampling device, which will then be analysed by Owlstone Medical to identify those that are associated with PH, in order to develop biomarker signatures that can help facilitate earlier detection of the disease.

Billy Boyle, co-founder and CEO at Owlstone Medical, said: "Owlstone Medical was founded with the objective of improving the early diagnosis of disease in order to save lives through the application of Breath Biopsy.

He continued to explain that the partnership will be "focused on improving the lives of those suffering from pulmonary hypertension and pulmonary arterial hypertension, and represents a tremendous opportunity to do just that. This is particularly true in underdiagnosed areas such as pulmonary hypertension, where early diagnosis is difficult and so screening has to be simple, reliable, and cost effective"

"We believe Breath Biopsy will deliver a program from discovery through to the launch of a test to the market, and this novel approach will make a real difference for the healthcare of patients suffering from pulmonary hypertension."

Pulmonary hypertension is a progressive cardiopulmonary disease where the blood pressure increases in the vessels that transport blood from the heart to the lungs, placing strain on the right side of the heart and often leading to heart failure.

Owlstone, Actelion ink collab pulmonary hypertension breath test dev deal - Mass Device

Posted: 20 May 2019 12:00 AM PDT

Share

Actelion, Owlstone Medical

Owlstone Medical said today that it inked a strategic collaborative deal with Johnson & Johnson's (NYSE:JNJ) Actelion to discover and validate a breath-based test intended for the early diagnosis of pulmonary hypertension and its subtypes.

Cambridge, UK-based Owlstone Medical said that the collaborative development program will be funded solely by Actelion, and that it will initially involve collecting breath exhaled volatile organic compounds from over 1,000 patients using Owlstone's ReCIVA sampling device.

Samples collected will be analyzed by Owlstone Medical to identify those associated with pulmonary hypertension in an effort to develop a biomarker signature to facilitate earlier detection of the disease.

"Owlstone Medical was founded with the objective of improving the early diagnosis of disease in order to save lives through the application of Breath Biopsy. This strategic collaboration with Actelion, which is focused on improving the lives of those suffering from PH and PAH, represents a tremendous opportunity to do just that. This is particularly true in underdiagnosed areas such as PH, where early diagnosis is difficult and so screening has to be simple, reliable, and cost effective. We believe Breath Biopsy will deliver a program from discovery through to the launch of a test to the market, and this novel approach will make a real difference for the healthcare of patients suffering from PH," Owlstone Medical co-founder & CEO Billy Boyle said in a press release.

Last October, Owlstone Medical said that it raised $50 million (UK £38 million) in a round of financing, with funds slated to help support the targeted launch of its breath biopsy kits and continued development of its technology platforms.

textadimage At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.

Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.

REGISTER NOW

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more